Zusammenfassung
Die Komplexität der Behandlung bipolarer affektiver Störungen ergibt sich daraus, dass im Krankheitsverlauf fünf verschiedene Symptomkonstellationen auftreten können (Depression, Hypomanie, Manie, gemischte Episode, Rapid Cycling), was oft zu einer polypharmazeutischen Therapie führt. So muss mehr als bei der Behandlung jeder einzelnen Episode der langfristige Verlauf und dessen besondere polare Natur berücksichtigt werden.
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Armani F, Andersen ML, Galduróz JC (2014) Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology (Berl) 231(4):639–649
Bowden CL, Singh V, Weisler R (2012) Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatr Scand 126(5):342–350
Cipriani A, Barbui C, Salanti G et al (2011) Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 378(9799):1306–1315
Cipriani A, Reid K, Young AH et al (2013) Valproic acid, valproate and divalproex in the main tenance treatment of bipolar disorder. Cochrane Database Syst Rev 10:CD003196
Citrome L, Ketter TA, Cucchiaro J et al (2014) Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 155:20–27
Crump C, Sundquist K, Winkleby MA et al (2013) Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 70(9):931–939
DGBS e.V., DGPPN e.V (2012) S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 1.0, Mai 2012
Ghaemi SN, Ostacher MM, El-Mallakh RS et al (2010) Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 71(4):372–380
Goss AJ, Kaser M, Costafreda SG et al (2013) Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 74(11):1101–1107
Grover S, Kukreti R (2014) HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 24(2):94–112
Grunze H, Vieta E, Goodwin GM et al (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 14(3):154–219
Fountoulakis KN, Kasper S, Andreassen O et al (2012) Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 262(Suppl 1):1–48
Leon AC, Solomon DA, Li C et al (2012) Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study. Am J Psychiatry 169(3):285–291
Li CT, Bai YM, Huang YL et al (2011) Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry 200(1):45–51
Loebel A, Cucchiaro J, Silva R et al (2014a) Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 171(2):160–168
Loebel A, Cucchiaro J, Silva R et al (2014b) Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 171(2):169–177
McIntyre RS, McElroy SL, Eudicone JM et al (2011) A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder. Prim Care Companion CNS Disord 13(6)
McKnight RF, Adida M, Budge K (2012) Lithium toxicity profile: a systematic review and meta-analysis. The Lancet 379(9817):721–728
Merikangas KR, Jin R, He JP et al (2011) Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68(3):241–251
Naughton M, Clarke G, O’Leary OF et al (2014) A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord 156:24–35
Pacchiarotti I, Bond DJ, Baldessarini RJ et al (2013) The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 170(11):1249–1262
Parikh SV, LeBlanc SR, Ovanessian MM (2010) Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEPBD). Can J Psychiatry 55(3):136–143
Post RM, Leverich GS, Altshuler LL et al (2012) Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J Clin Psychiatry 73(7):924–930
Viktorin A, Lichtenstein P, Thase ME et al (2014) The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. doi: 10.1176/appi.ajp.2014.13111501 (Epub ahead of print)
Yatham LN, Fountoulakis KN, Rahman Z et al (2013) Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord 147(1–3):365–372
Young AH, McElroy SL, Bauer M et al; EMBOLDEN I (Trial 001) Investigators (2010) A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 71(2): 150–162
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Benkert, O. (2015). Medikamente zur Behandlung bipolarer affektiver Störungen. In: Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54769-0_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-54769-0_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54768-3
Online ISBN: 978-3-642-54769-0
eBook Packages: Medicine (German Language)